Understanding low INR in clinical practice

Elaine M. Hylek; Adam J. Rose

doi:10.1160/TH09-01-0067

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(03): 417-418
DOI: 10.1160/TH09-01-0067

Editorial Focus

Schattauer GmbH

Understanding low INR in clinical practice

Authors

Elaine M. Hylek

¹Department of Medicine, Research Unit-Section of General Internal Medicine, Boston University School of Medicine, Boston, Massachussetts, USA
Adam J. Rose

¹Department of Medicine, Research Unit-Section of General Internal Medicine, Boston University School of Medicine, Boston, Massachussetts, USA

²Center for Health Quality, Outcomes, and Economic Research, Bedford VA Medical Center, Bedford, Massachussetts, USA

Abstract

Full Text

References

References
1 Spranca M, Minsk E, Baron J. Omission and comission in judgement and choice. J Exp Soc Psychol 1991; 27: 76-105.
2 Hayward RA, Asch SM, Hogan MM. et al. Sins of omission: getting too little medical care may be the greatest threat to patient safety. J Gen Intern Med 2005; 20: 686-691.
3 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
4 Fihn SD, Callahan CM, Martin DC. et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970-979.
5 Gage BF, Yan Y, Milligan PE. et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719.
6 Schulman S, Beyth RJ, Kearon C. et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 257S-298S.
7 DiMarco JP, Flaker G, Waldo AL. et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 650-656.
8 Choudhry NK, Soumerai SB, Normand SL. et al. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 2006; 119: 607-615.
9 Go AS, Hylek EM, Chang Y. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. J Am Med Assoc 2003; 290: 2685-2692.
10 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
11 Jones M, McEwan P, Morgan CL. et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 472-477.
12 Menzin J, Boulanger L, Hauch O. et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother 2005; 39: 446-451.
13 McCormick D, Gurwitz JH, Goldberg RJ. et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001; 161: 2458-2463.
14 Matchar DB, Samsa GP, Cohen SJ. et al. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 2002; 113: 42-51.
15 Kucher N, Connolly S, Beckman JA. et al. International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med 2004; 164: 2176-2179.
16 Garcia DA, Regan S, Henault LE. et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168: 63-69.
17 Hylek EM, Go AS, Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. New Engl J Med 2003; 349: 1019-1026.
18 Rombouts E, Rosendaal FR, Van der Meer FJ. Subtherapeutic oral anticoagulant therapy: Frequency and risk factors. Thromb Haemost 2009; 101: 552-556.
19 Fihn SD, Gadisseur AA, Pasterkamp E. et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90: 260-266.
20 van Geest-Daalderop JH, Hutten BA, Péquériaux NC. et al. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for the assessment of the dose. Thromb Haemost 2007; 98: 738-746.
21 Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100: 1052-1057.
22 van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy.. An analysis of risk factors. Arch Intern Med 1993; 153: 1557-1562.
23 Gadisseur AP, van der Meer FJ, Adriaansen HJ. et al. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002; 117: 940-946.
24 Visser LE, van Schaik RH, van Vliet M. et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92: 61-66.